Neurocrine Biosciences (NBIX) Total Current Liabilities (2010 - 2026)

Neurocrine Biosciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $831.7 million for Q1 2026.

• Quarterly Total Current Liabilities rose 59.06% year-over-year to $831.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $831.7 million (up 59.06% YoY) and the FY2025 annual result came in at $743.4 million, up 46.43% from the prior year.
• Total Current Liabilities was $831.7 million for Q1 2026 at Neurocrine Biosciences, up from $743.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $831.7 million in Q1 2026 and bottomed at $253.5 million in Q1 2022.
• A 5-year average of $540.9 million and a median of $537.7 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 118.76% — and 2024, when it sank 37.87%.
• Neurocrine Biosciences' Total Current Liabilities stood at $537.7 million in 2022, then gained by 21.78% to $654.8 million in 2023, then decreased by 22.46% to $507.7 million in 2024, then jumped by 46.43% to $743.4 million in 2025, then increased by 11.88% to $831.7 million in 2026.
• Business Quant data shows NBIX's Total Current Liabilities at $831.7 million in Q1 2026, $743.4 million in Q4 2025, and $638.0 million in Q3 2025.